Top in endocrinology: Generic glucagon, fish consumption and diabetes risk

The FDA approval of generic glucagon for the treatment of severe hypoglycemia was the top story in endocrinology last week.

Another top story was about study findings that suggest high fish consumption may offset the risk for autoimmune diabetes.

Read these and more top stories in endocrinology below:

FDA approves generic glucagon for treating severe hypoglycemia

The FDA has approved the first generic glucagon for injection, commonly used to treat severe hypoglycemia in individuals with diabetes taking insulin, according to an agency press release. Read more.

High fish consumption may ‘counteract’ autoimmune diabetes risk

Adults positive for glutamic acid decarboxylase antibodies were more than twice as likely to develop adult-onset diabetes if they had low fish intake compared with high fish intake, according to findings published in Diabetes Care. Read more.

Type 2 diabetes, moderate alcohol consumption increase advanced fibrosis risk in NAFLD

Moderate alcohol consumption was associated with an increased risk for advanced fibrosis in nonalcoholic fatty liver disease, with the risk highest among those with type 2 diabetes, according to study data. Read more.

Glucose levels, time in range improve on days with exercise in type 1 diabetes

Individuals with type 1 diabetes had lower mean glucose levels and spent more time in range on days they exercised compared with sedentary days, according to data published in Diabetes Technology & Therapeutics. Read more.

No adverse events reported in cohort of high-risk men receiving testosterone therapy

Testosterone therapy with intramuscular testosterone undecanoate did not result in any adverse cardiovascular or prostate events in a cohort of men with obesity, type 2 diabetes and functional hypogonadism, clinical trial data showed. Read more.